Horizon Pharma Inc. (NASDAQ:HZNP) traded up 1.8% during trading on Friday . The stock traded as high as $19.25 and last traded at $19.02, with a volume of 1,640,269 shares changing hands. The stock had previously closed at $18.69.

A number of equities research analysts have recently issued reports on HZNP shares. Stifel Nicolaus reissued a “buy” rating and issued a $45.00 price target on shares of Horizon Pharma in a report on Wednesday, July 6th. Brean Capital reissued a “buy” rating on shares of Horizon Pharma in a report on Thursday. Mizuho reissued a “buy” rating and issued a $25.00 price target (down from $34.00) on shares of Horizon Pharma in a report on Tuesday, May 3rd. Zacks Investment Research raised shares of Horizon Pharma from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a report on Monday. Finally, Piper Jaffray Cos. reissued a “buy” rating and issued a $44.00 price target on shares of Horizon Pharma in a report on Wednesday, April 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Horizon Pharma presently has an average rating of “Buy” and a consensus price target of $29.23.

The stock has a 50-day moving average of $17.44 and a 200 day moving average of $17.06. The stock has a market cap of $3.07 billion and a PE ratio of 248.31.

Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported $0.34 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.04. The company had revenue of $204.70 million for the quarter, compared to the consensus estimate of $197.73 million. The company’s revenue was up 80.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.18 earnings per share. On average, equities analysts forecast that Horizon Pharma Inc. will post $2.35 EPS for the current fiscal year.

In related news, Director Virinder Nohria sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 15th. The stock was sold at an average price of $17.69, for a total transaction of $442,250.00. Following the completion of the transaction, the director now directly owns 189,836 shares in the company, valued at approximately $3,358,198.84. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Other hedge funds and institutional investors recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its position in shares of Horizon Pharma by 104.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 557,772 shares of the biopharmaceutical company’s stock worth $12,089,000 after buying an additional 284,359 shares during the period. Redwood Investments LLC increased its position in shares of Horizon Pharma by 43.8% in the fourth quarter. Redwood Investments LLC now owns 111,682 shares of the biopharmaceutical company’s stock worth $2,420,000 after buying an additional 34,008 shares during the period. Hodges Capital Management Inc. increased its position in shares of Horizon Pharma by 4.1% in the fourth quarter. Hodges Capital Management Inc. now owns 1,571,794 shares of the biopharmaceutical company’s stock worth $34,061,000 after buying an additional 61,454 shares during the period. Systematic Financial Management LP increased its position in shares of Horizon Pharma by 100.4% in the fourth quarter. Systematic Financial Management LP now owns 152,340 shares of the biopharmaceutical company’s stock worth $3,301,000 after buying an additional 76,335 shares during the period. Finally, Zweig DiMenna Associates LLC increased its position in shares of Horizon Pharma by 1,466.9% in the fourth quarter. Zweig DiMenna Associates LLC now owns 433,250 shares of the biopharmaceutical company’s stock worth $9,389,000 after buying an additional 405,600 shares during the period.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.